Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24628147 | 0.89 | SIGMAR1 (0.58) | SIGMAR1CXCR3ACHECCR3MC4R | |
| SCHEMBL18177857 | 0.80 | TRPV6 (0.54) | KDM4EACHEBCHEBACE1SMN1; SMN2 | |
| SCHEMBL1143256 | 0.78 | SIGMAR1 (0.60) | KDM4ESIGMAR1KMT2ACXCR3ACHE | |
| SCHEMBL17166950 | 0.77 | KDM4E (0.57) | KDM4EPKMKMT2A | |
| SCHEMBL13698447 | 0.77 | KDM4E (0.57) | KDM4EPKMKMT2A | |
| SCHEMBL11315406 | 0.77 | KDM4E (0.57) | KDM4EPKMKMT2A | |
| SCHEMBL27979614 | 0.75 | KDM4E (0.50) | KDM4EPKMKMT2A | |
| SCHEMBL3351443 | 0.75 | SIGMAR1 (0.55) | SIGMAR1ACHEBCHEBACE1CCR3 | |
| SCHEMBL6800130 | 0.75 | SIGMAR1 (0.55) | SIGMAR1ACHEBCHEBACE1CCR3 | |
| SCHEMBL4797625 | 0.74 | SIGMAR1 (0.69) | SIGMAR1ACHECCR3MC4RRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | INVITROGEN CORPORATION | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160312253-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885SIGMAR1 3599/4885PKM 493/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885SIGMAR1 3599/4885PKM 493/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | KDM4E 1755/4885SIGMAR1 3599/4885PKM 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.